Nuvectis Pharma, Inc. Annual Operating Income (Loss) in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nuvectis Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2023.
  • Nuvectis Pharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$4.36M, a 29.2% increase year-over-year.
  • Nuvectis Pharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$20.3M, a 11.2% increase year-over-year.
  • Nuvectis Pharma, Inc. annual Operating Income (Loss) for 2023 was -$22.9M, a 19% decline from 2022.
  • Nuvectis Pharma, Inc. annual Operating Income (Loss) for 2022 was -$19.2M, a 49.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$22.9M -$3.66M -19% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$19.2M -$6.34M -49.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$12.9M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.